Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

Stock Information for Marker Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marker Therapeutics Inc.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During "J.P. Morgan Week 2024"
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.